DECIPHERA PHARMACEUTICALS IN (DCPH)
US24344T1016 - Common Stock
| 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 83.51M | 64.74M | 87.06M | 105.90M | 120.32M | |||
| Marketable Securities | 222.71M | 259.75M | 198.57M | 446.03M | 459.26M | |||
| Receivables | 31.95M | 22.43M | 20.59M | 13.90M | N/A | |||
| Inventories | 21.21M | 20.56M | 14.13M | 5.72M | N/A | |||
| Other Current Assets | 21.72M | 25.48M | 18.66M | 12.49M | 13.83M | |||
| Total Current Assets | 381.10M | 392.96M | 339.01M | 584.03M | 593.41M | |||
| Non-Current Assets | ||||||||
| PPE Net | 37.49M | 43.25M | 45.41M | 45.92M | 27.49M | |||
| Investments And Advances | 46.70M | 14.55M | 41.95M | 9.38M | N/A | |||
| Other Non-Current Assets | 8.28M | 3.28M | 3.11M | 3.10M | 1.51M | |||
| Total Non-Current Assets | 92.47M | 61.08M | 90.47M | 58.40M | 29.00M | |||
| TOTAL ASSETS | 473.57M | 454.04M | 429.48M | 642.43M | 622.41M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | N/A | N/A | N/A | N/A | 0.00 | |||
| Accrued Expenses | 47.73M | 50.61M | 54.13M | 54.30M | 40.46M | |||
| Accounts Payable | 26.48M | 18.61M | 13.13M | 12.31M | 19.57M | |||
| Other Current Liabilities | 26.07M | 17.25M | 29.51M | 3.38M | N/A | |||
| Total Current Liabilities | 100.28M | 86.47M | 96.77M | 69.99M | 60.04M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Other Non-Current Liabilities | 22.38M | 25.88M | 27.99M | 28.76M | 15.90M | |||
| Total Non-Current Liabilities | 22.38M | 25.88M | 27.99M | 28.76M | 15.90M | |||
| TOTAL LIABILITIES | 122.65M | 112.35M | 124.76M | 98.76M | 75.94M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -1.43B | -1.23B | -1.05B | -754.47M | -487.98M | |||
| Additional Paid In Capital | 1.78B | 1.58B | 1.36B | 1.30B | 1.03B | |||
| Common Shares | 805.00K | 676.00K | 585.00K | 576.00K | 516.00K | |||
| Other Shareholders' Equity | 577.00K | -983.00K | 51.00K | 111.00K | N/A | |||
| Shares Outstanding | 80.50M | 67.64M | 58.55M | 57.60M | 51.62M | |||
| Tangible Book Value per Share | 4.36 | 5.05 | 5.20 | 9.44 | 10.59 | |||
| Total Shareholders' Equity | 350.92M | 341.69M | 304.72M | 543.68M | 546.47M | |||
| TOTAL LIABILITIES AND EQUITY | 473.57M | 454.04M | 429.48M | 642.43M | 622.41M | |||
| Statistics | ||||||||
| Debt/Equity | N/A | N/A | N/A | N/A | N/A | |||
| Current Ratio | 3.80 | 4.54 | 3.50 | 8.34 | 9.88 | |||
| Return On Assets (ROA) | -41.16% | -39.41% | -69.84% | -41.48% | -30.89% | |||
| Return On Equity (ROE) | -55.55% | -52.37% | -98.44% | -49.02% | -35.18% | |||
All data in USD